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Abstract
 
Background.
 
A number of studies have dem-
onstrated the efficacy of oral anticoagulant therapy in re-
ducing the risk of stroke and systemic embolism in pa-
tients with nonrheumatic atrial fibrillation. However, both
the targeted and the actual levels of anticoagulation dif-
fered widely among the studies, and a number of studies
failed to report standardized prothrombin-time ratios as
international normalized ratios (INRs). We therefore per-
formed an analysis to determine the intensity of oral anti-
coagulant therapy in nonrheumatic atrial fibrillation that
provides the best balance between the prevention of
thromboembolism and the occurrence of bleeding compli-
cations.
 
Methods.
 
We calculated INR-specific incidence rates
for both ischemic and major hemorrhagic events occur-
ring in 214 patients who received anticoagulant therapy in
the European Atrial Fibrillation Trial, a secondary-preven-
tion trial in patients with nonrheumatic atrial fibrillation and
a recent episode of minor cerebral ischemia.
 
Results. 
 
The optimal intensity of anticoagulation was
found to lie between an INR of 2.0 and an INR of 3.9. No
treatment effect was apparent with anticoagulation below
an INR of 2.0. The rate of thromboembolic events was
lowest at INRs from 2.0 to 3.9, and most major bleeding
complications occurred with treatment at intensities with
INRs of 5.0 or above.
 
Conclusions.
 
To achieve optimal levels of anticoagu-
lation with the lowest risk in patients with atrial fibrillation
and a recent episode of cerebral ischemia, the target val-
ue for the INR should be set at 3.0, and values below 2.0
and above 5.0 should be avoided. (N Engl J Med 1995;
333:5-10.)
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HE efficacy of oral anticoagulant therapy in reduc-
ing the risk of stroke and systemic embolism has
been demonstrated for both primary and secondary
prevention in patients with nonrheumatic atrial fibrilla-
tion. Reductions in the risk of thromboembolic events
(usually defined as ischemic stroke and systemic embo-
lism) range from 37 to 86 percent, but major bleeding
complications occur at rates of 5 to 28 per 1000 patient-
years.
 
1-7
 
 However, the targeted therapeutic ranges, as
well as the levels of anticoagulant control actually
obtained, differed widely among studies. In primary-
prevention trials, for example, 8 to 40 percent of the
international normalized ratios (INRs) fell below the
targeted range, and 1 to 17 percent exceeded the up-
per limit.
 
1-6
 
 Only a few studies originally recorded pro-
thrombin-time ratios in INR equivalents to account for
differences in preparations of thromboplastin.
 
8
 
 It has
therefore been suggested that the intention-to-treat
analyses sometimes used
 
7 
 
may have led to incomplete
or misleading conclusions.
 
9
 
 Additional analyses are re-
quired to determine what intensity of oral anticoagu-
lant therapy in patients with nonrheumatic atrial fibril-
lation offers the best balance between the prevention of
thromboembolism and the occurrence of bleeding com-
plications.
Using a recently proposed method to determine the
optimal intensity of oral anticoagulant therapy,
 
10
 
 we
calculated INR-specific incidence rates for ischemic as
well as major hemorrhagic events occurring in the an-
ticoagulation cohort of the European Atrial Fibrillation
Trial, a secondary-prevention trial in patients with non-
rheumatic atrial fibrillation and a recent transient is-
chemic attack or minor ischemic stroke.
 
7
 
M
 
ETHODS
 
Patients
 
The study group consisted of patients in the European Atrial Fi-
brillation Trial who had been randomly assigned to oral anticoagu-
lant therapy. This study was a randomized, multicenter clinical trial
that aimed to assess the therapeutic efficacy and safety of oral an-
ticoagulants and aspirin for the prevention of vascular events in
patients with nonrheumatic atrial fibrillation and a recent minor cer-
ebral ischemic event. Patients eligible for treatment with oral antico-
agulants were randomly assigned to open anticoagulant treatment
(INR, 2.5 to 3.9) or double-blind treatment with either aspirin (300
mg per day) or placebo. Informed consent was obtained from all
study patients. The study protocol was reviewed and approved by the
institutional review boards of all participating hospitals.
 
Anticoagulant Control
 
The choice of anticoagulant was left to the discretion of the phy-
sician and depended largely on that physician’s personal experience
with the various agents and on their availability. Most often, physi-
cians prescribed relatively short-acting preparations of acenocou-
marol, but warfarin and fenprocoumon were also used. The dose of
anticoagulant was adjusted on the basis of the patient’s prothrom-
bin time. To accommodate variations in the composition and re-
sponsiveness of the thromboplastins and in the methods needed to
measure the prothrombin time, all the centers were asked to use
only calibrated commercial preparations. This would allow pro-
thrombin-time values to be reported in INR equivalents.
 
11,12
 
 All the
centers used well-known, standardized thromboplastins. The col-
laborating investigators were urged to use conversion tables avail-
able from the laboratories involved, and these tables were checked
during site visits. The INRs were to be maintained at a target value
of 3.0 (range, 2.5 to 3.9).
 
13,14
 
 The prothrombin time had to be mon-
itored at least once a month, and the resulting values were reported
to the study office every four months, when the patient came for a
follow-up visit. When the intensity of anticoagulation consistently
fell below the proposed range, the centers were notified by the study
office.
 
Calculation of INR-Specific Event Rates
 
The data required to calculate INR-specific event rates included
both information on the occurrence of events (the numerator) and
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the time the patient spent in each range of anticoagulation intensity
(the denominator).
 
Definitions of Events
 
To assess the optimal intensity of anticoagulation, we classified the
outcome events as much as possible as ischemic or hemorrhagic com-
plications. The primary measure of outcome in the trial was the com-
posite event of death from cardiovascular causes, nonfatal stroke (in-
cluding intracranial hemorrhage), nonfatal myocardial infarction, or
systemic embolism, whichever occurred first. Death from cardiovas-
cular causes included sudden death (in which the death was seen by
an eyewitness, with a reliable observation of the time between the on-
set of symptoms and death, or the patient was found dead) or death
from stroke, myocardial infarction, congestive heart failure, systemic
embolism, noncerebral bleeding, or other cardiovascular causes (in-
cluding pulmonary embolism and peripheral vascular disease). Ex-
cept for documented extracerebral hemorrhages, all these events were
classified as ischemic.
The diagnosis of nonfatal stroke required the finding of a focal
neurologic deficit that persisted for more than 24 hours. Computed
tomographic (CT) scans performed at the time of the outcome event
were centrally audited by physicians who were unaware of the as-
signed treatment. On the basis of these scans, the distinction between
ischemic stroke, ischemic stroke with hemorrhagic transformation,
and primary intracerebral hemorrhage was made. The diagnosis of
systemic embolism was defined clinically as an abrupt vascular insuf-
ficiency of the limbs or internal organs associated with clinical or ra-
diologic evidence of arterial occlusion, in the absence of previous ob-
structive disease; it did not include pulmonary embolism. Myocardial
infarction had to be documented by at least two of the following char-
acteristics: a history of chest discomfort, specific cardiac-enzyme lev-
els more than twice the upper limit of normal, and the development
of Q waves on a standard 12-lead electrocardiogram.
The occurrence of bleeding complications was recorded at each
follow-up visit for each patient. Hemorrhagic episodes were classified
according to severity. Fatal bleeding complications had to be docu-
mented by convincing clinical evidence or autopsy. Nonfatal bleeding
complications were considered to be major if admission to the hospi-
tal and at least one transfusion or surgery were necessary, or if the
complication caused a permanent increase in disability. Nosebleeds,
bruising, hematemesis, and hematuria were considered to be minor
if no transfusion or operative intervention was required. All events
were classified independently by at least three members of the audit-
ing committee for outcome events, after the medical records had
been summarized and edited to ensure that the reviewers remained
unaware of the assigned treatment. Differences of opinion were dis-
cussed in the Executive Committee, which was also blinded, and
were decided by a majority vote.
The INR measured at the time of an event was recorded on the
same form on which the event was reported. If no INR measurement
was available at the time of the event, the most recent measurement
obtained within the preceding 28 days was used.
 
Calculation of Observation Times for Different INR Levels
 
The total time each patient was observed was tabulated from the
patient’s entry into the study until the final visit in April 1993, the
occurrence of an event, or 28 days after the discontinuation of anti-
coagulant therapy, whichever came first. This observation time was
stratified according to INR level. Half the time from one INR meas-
urement to the previous measurement and half the time to the sub-
sequent measurement were assigned as the period when that INR
measurement was in effect.
 
15
 
 When more than 56 days passed be-
tween INR measurements for a patient, no more than 28 days of that
period could be assigned to each measurement; the intervening days,
for which the intensity of anticoagulation was undefined, were as-
signed to a separate category known as “unknown INR.”
 
Statistical Analysis
 
Event rates, 95 percent confidence intervals, and event-rate ratios
were derived by standard calculations, based on the assumption of a
Poisson distribution of the number of events, with an Egret statistical
package.
 
16
 
 A multivariate Poisson regression model
 
17
 
 was used to
control for confounding due to possible differences in age, systolic
blood pressure, history of ischemic heart disease, and the presence
of an enlarged heart (cardiothoracic ratio, >50 percent) as seen on
chest radiography. These variables have been identified as the most
important predictors of recurrent cardiovascular events in patients
treated with oral anticoagulants (unpublished data). In addition, oth-
er studies have identified age and systolic blood pressure as predic-
tors of bleeding complications.
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R
 
ESULTS
 
From October 1988 through May 1992, 1007 pa-
tients were enrolled in the European Atrial Fibrillation
Trial. Of 669 patients eligible for anticoagulant thera-
py, 225 were randomly assigned to treatment with oral
anticoagulants. Two patients refused to begin treat-
ment with anticoagulants, and treatment was stopped
within seven days in one patient because of erratic com-
pliance. In another eight patients no INR values were
obtained, because before their first follow-up visit they
either had a major outcome event or discontinued anti-
coagulant treatment (four patients each). These 11 pa-
tients were excluded from further analysis. For the re-
maining 214 patients, a total of 72 patient-years spent
receiving the treatment were unaccounted for because
there was insufficient information on INR measure-
ments. The analyses reported here were based on the
remaining 377 patient-years. Fifty-five percent of the
patients were men, their mean age was 71 years, and
43 percent had a history of hypertension.
 
Intensity of Anticoagulation
 
A total of 4883 INR values were reported to the
study office, with a median of 21 determinations per
patient (range, 1 to 63). Given an average follow-up of
2.1 years while the patients were receiving treatment,
INR determinations were reported approximately every
5 weeks. INR values for 47 patients were unavailable at
some time during the trial for periods exceeding three
months, indicating that for these patients only assump-
tions can be made about the overall intensity of antico-
agulation. Figure 1 shows the intensity of anticoagula-
tion that was obtained. Fifty-six percent of all available
INR measurements were within the target range of 2.5
to 3.9. Thirty-five percent of the measurements were
below this range, and 9 percent were above it. These
percentages were similar for all age groups studied (un-
der 65 years, from 65 through 75 years, and over 75
years).
 
INR-Specific Event Rates
 
An overview of all events is given in Table 1, and the
corresponding INR-specific event rates are shown in
Table 2. Higher INR levels were associated with in-
creases in the incidence of not only major bleeding
complications, but also presumed ischemic events, in-
dicating that the latter could theoretically have includ-
ed unrecognized hemorrhagic events (e.g., in the five
sudden deaths and the three strokes in patients for
whom no CT scans were performed). Because of the
relatively small number of events, further analyses
were restricted to the 39 outcome events characterized
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by an ischemic episode (in 23 patients), a major hem-
orrhagic episode (in 13), or an undetermined episode
(in 3), whichever came first.
For these 39 combined events, the total number of
patient-years included within the INR-specific intervals
was as follows: 40 patient-years for INRs of less than
2.0, 186 years for INRs from 2.0 to 2.9, 114 years for
INRs from 3.0 to 3.9, 27 years for INRs from 4.0 to 4.9,
and 10 years for INRs of 5.0 or more. For 32 of the 39
outcome events, INR measurements obtained at the
time of the event were available. INR-specific incidence
rates and the corresponding 95 percent confidence in-
tervals are shown in Figure 2. The highest event rates
corresponded to INR values below 2.0 (predominantly
ischemic events; rate, 18 per 100 patient-years) and
above 5.0 (predominantly hemorrhagic events; rate, 60
per 100 patient-years). The lowest incidence rate for is-
chemic and hemorrhagic events combined was found at
INRs from 2.0 to 3.9. Multivariate Poisson regression
analyses were performed to assess the independent risk
of an outcome event for INR-specific intervals, after
control for age, systolic blood pressure at entry into the
study, history of ischemic cardiac disease, and cardio-
megaly (Table 3).
As compared with therapy producing an INR below
2.0, anticoagulant therapy producing an INR from 2.0
to 2.9 reduced the incidence of events by 80 percent
(rate ratio, 0.2; 95 percent confidence interval, 0.1 to
0.6). This effect was slightly less in the case of therapy
producing an INR from 3.0 to 3.9 (rate ratio, 0.4; 95
percent confidence interval, 0.1 to 1.1). At higher inten-
sities the event rate was increased, largely because of
an increased rate of hemorrhagic complications (Fig.
2). With INRs from 4.0 to 4.9, the rate ratio for vascular
events and major hemorrhages was 1.6 (95 percent
confidence interval, 0.6 to 4.6), and with INRs of 5.0 or
above this rate ratio increased even further, to 3.6
(95 percent confidence interval, 1.2 to 11). In these
analyses both age and the presence of cardiomegaly
remained important risk factors for recurrent events
(thromboembolic or hemorrhagic). Additional analyses
 
Figure 1. Intensity of Anticoagulation in the Study Patients, According to Reported INR Values and Person-Years of Exposure to Var-
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The left-hand panel shows the percentage of all reported INRs that were within the given ranges. The right-hand panel shows the
number of person-years that were associated with each INR range. If more than 56 days passed between consecutive INR measure-
ments, 28 days were assigned to each measurement and the INR value of the remaining days was considered to be unknown.
 
*Includes one death.
†Of these three patients, one had epileptic seizures after which
left-sided hemiparesis was found. The patient died 20 days later
(INR at time of event, 4.2). The second patient had the sudden
onset of headache, with nausea and rapid loss of consciousness,
and died the same day (INR, unknown). The third patient was
unconscious on admission, with Cheyne–Stokes breathing, pin-
point pupils, and bilateral Babinski signs. This patient died three
hours later (INR, 2.8).
 
Table 1. First Ischemic and Hemorrhagic 
Events Occurring among the 214 Study
Patients.
 
O
 
UTCOME
 
 E
 
VENT
 
N
 
O
 
. 
 
OF
 
 
E
 
VENTS
 
Ischemic
 
Sudden death
Fatal congestive heart failure
Other deaths from cardiovascular causes
All myocardial infarctions
All systemic embolism
Ischemic stroke
Hemorrhagic infarction
All
5
3
1
3
2
10
1
25
 
Major hemorrhagic
 
Respiratory tract
Gastrointestinal tract
Urogenital tract
Cerebral
Anemia
Other
All
2*
4*
1
0
1
5
13
 
Uncertain
 
Strokes, no CT available 3†
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showed that an age over 75 years was associated with
a higher risk of major bleeding (rate ratio, 3.6; 95 per-
cent confidence interval, 1.0 to 13) independently of the
therapeutic intensity of anticoagulation. Systolic blood
pressure over 160 mm Hg at study entry was not asso-
ciated with a higher rate of major bleeding complica-
tions.
 
D
 
ISCUSSION
 
In our study of patients with nonrheumatic atrial fi-
brillation and recent cerebral ischemia, anticoagulation
resulting in an INR of 2.0 to 3.9 offered the best bal-
ance between recurrent ischemic events and major
bleeding complications. It therefore seems that antico-
agulation with a target intensity resulting in an INR of
3.0 may provide an optimal therapeutic effect with the
lowest risk of bleeding. These findings are in agree-
ment with guidelines formulated in recent studies
 
19
 
 and
the guidelines of the American College of Chest Phy-
sicians,
 
20,21
 
 but they may suggest a
slightly lower intensity of anticoagu-
lation than was recommended in the
Dutch guidelines for high-risk pa-
tients (target INR, 3.5; range, 3.0 to
4.5).
 
22
 
 Because of the limited number
of observations, the present study
contains insufficient evidence to re-
fute the Dutch guidelines. Therefore,
future studies of the optimal intensi-
ty of anticoagulation in other popula-
tions of patients are needed to settle
the issue definitively. Two ongoing
primary-prevention studies, the Pri-
mary Prevention of Arterial Throm-
boembolic Processes in Atrial Fi-
brillation Study (PATAF) and the
second Atrial Fibrillation, Aspirin, Anticoagulant Study
(AFASAK II), are comparing various targets of antico-
agulation. Until the results of these studies are avail-
able, one should use caution in extrapolating our results
to primary prevention.
The analyses of efficacy presented here can provide
clinicians with helpful insights, but they should not re-
place intention-to-treat analyses. The effect of erratic
compliance with anticoagulation therapy can be as-
sessed by this method, but the effects of withdrawal
from anticoagulant treatment for reasons other than
major bleeding complications (e.g., recurrent minor
bleeding and reluctance by the patient to adhere to
stringent regimens in which prothrombin time is con-
trolled) are lost in such an analysis. Intention-to-treat
analyses allow more general conclusions with regard to
the strategy of prescribing anticoagulants, regardless
of the intensity of coagulation attained, which, even
with intensive control in the laboratory, depends largely
on characteristics of the patient that are not always
easily defined or recognized.
 
23
 
In our study, the incidence of major bleeding compli-
cations related to oral anticoagulant therapy was 2.8
per 100 patient-years, slightly higher than in the pri-
mary-prevention studies of patients with nonrheumatic
atrial fibrillation but within the ranges reported by oth-
er studies that considered a wider range of indica-
tions.
 
15,24,25
 
 Differences in the intensity of anticoagula-
tion may explain this difference in part, but the higher
mean age of our patients may also have influenced the
findings. The relation between higher age and an in-
creased risk of major hemorrhagic events is still contro-
versial,
 
26-28 
 
but it seems plausible to expect a higher risk
of complications because of an increase in coexisting
conditions. This theory is supported by the findings of
the recently completed second study by the Stroke Pre-
vention in Atrial Fibrillation (SPAF II) investigators.
 
29
 
In our study population, no association was found be-
tween high systolic blood pressure or a history of hy-
pertension, on the one hand, and the risk of bleeding
on the other.
 
24,28,30 
 
Possible explanations may be that
the study sample was small, that only patients with ad-
 
*Numbers in parentheses are numbers of fatal events.
†Includes one patient with stroke of uncertain cause.
 
Table 2. First Ischemic and Hemorrhagic Complications among the Study Patients,
According to the INR at the Time of the Event.
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Figure 2. INR-Specific Incidence Rates for the Occurrence of a
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equately controlled hypertension were enrolled, and
that the blood-pressure measurements obtained at study
entry that were used in this analysis were probably un-
representative of systolic blood pressures during the
rest of the study period.
In conclusion, the optimal therapeutic range for an-
ticoagulation in the secondary prevention of vascular
events in relatively old patients with nonrheumatic atri-
al fibrillation who have recently had a minor cerebral
ischemic event lies between INRs from 2.0 to 3.9, with
a target INR of 3.0. When the INR is above 5.0, the risk
of serious bleeding complications becomes unaccept-
able, whereas no apparent reduction in thromboembol-
ic events was observed at INRs below 2.0.
 
We are indebted to Prof. E.A. Loeliger for his valuable advice and
comments.
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PPENDIX
 
The following centers and investigators participated in the Euro-
pean Atrial Fibrillation Trial. The number of patients randomized at
each center is given in parentheses.
 
Belgium:
 
 
 
Bruges
 
 — I. Dehaene, M. D’Hooghe, M. Marchau, and
M. van Zandijcke (3); 
 
Brussels
 
 —C. Delwaide, A. Depré, and E.C. La-
terre (3); 
 
Dendermonde
 
 — E. van Buggenhout (5);
 
 Geel
 
 — J. Schur-
mans, E. de Smet, and L. Swerts (4); 
 
Ghent
 
 — G. van den Abeele (4);
 
Leuven 
 
— H. Carton and P.M.A. Verdru (8); 
 
Mons
 
 — P.A. Indekeu
and D. Lam (13); 
 
Turnhout 
 
—
 
 
 
V. van den Bergh and L. Mol (1); and
 
Wilrijk
 
 — W. van Landegem and T. Strauven (2). 
 
Denmark:
 
 
 
Copen-
hagen
 
 — G. Boysen, J. Gyring, P. Petersen, and P. Würtzen-Nielsen
(11). 
 
France:
 
 
 
Besançon
 
 — T. Crepin-Leblond and T. Moulin (12); 
 
Bor-
deaux 
 
— S. Auriacombe and J.M. Orgogozo (2); 
 
Bourg-en-Bresse
 
 —
J. Boulliat (36); 
 
Brest
 
 — J.-Y. Goas and Y. Mocquard (5); 
 
Grenoble
 
 —
G. Besson and M. Hommel (5); 
 
Lille
 
 — C. Adnet-Bonte, E. Josien,
and H. Petit (2); 
 
Meaux
 
 — F. Chedru (5); 
 
Paris, Salpêtrière
 
 —
S. Evrard and M. Levasseur (2); 
 
Paris,
 
 
 
Raymond Garcin
 
 — J.L. Mas,
O. Meyniard, and M. Zuber (7); 
 
Paris,
 
 
 
Saint Antoine
 
 — P. Amarenco,
M.G. Bousser, and E. Roullet (2); 
 
Rennes
 
 — J.F. Pinel (5); 
 
Rouen
 
 —
E. Massardier and B. Mihout (2); 
 
Toulouse, Purpan
 
 — F. Chollet and
A. Rascol (1); and
 
 Tours
 
 — A. Autret and D. Saundeau (5). 
 
Germa-
ny:
 
 
 
Bochum
 
 — T. Büttner and W. Niemczyk (1); 
 
Giessen
 
 — K.D.
Böhm and C. Hornig (3); 
 
Heidelberg — 
 
W. Hacke, C. Heiss, and
R. Reuther (1); 
 
Homburg (Saar)
 
 — A. Haaß and M. Stoll (2); 
 
Mainz
 
— G. Krämer and G. Rothacher (10); 
 
Minden 
 
— M. Bauer, O. Busse,
S. Koch-Rose, and B. Mueffelmann (13); 
 
Tübingen
 
 — J. Dichgans and
C. Thomas (2); and 
 
Wuppertal
 
 — O.A.D. Hennen, J. Jörg, H. Schwan,
and R. Siepen (3). 
 
Israel:
 
 
 
Tel Aviv 
 
— N.M. Bornstein (15). 
 
Italy:
 
Ancona 
 
— B. Censori, M. Ceravolo, and L. Provinciali (7); 
 
Aosta
 
 —
G. D’Alessandro, E. Bottacchi, L. Carenini, and E. Duc (8); 
 
Bari
 
— F. Federico, A. Fiore, P. Lamberti, and P. Lattanzi (11); 
 
Bergamo
 
— M. Camerlingo, L. Casto, and A. Mamoli (11); 
 
Citta della Pieve
 
 —
G. Bénemìo, F. Boldrini, C. Gatteschi, G. Schillaci, P. Verdecchia,
and E. Vignai (8); 
 
Citta di Castello
 
 — G. Arcelli, S. Bravi, L. Coli,
L. Girelli, and A. Purro (9); 
 
Como
 
 — C. Del Favero, M. Guidotti,
G. Pellegrini, M. Santarone, and G. Tadeo (32); 
 
Milan, Niguarda
 
 —
G. Bottini, C. Canepari, and R. Sterzi (3); 
 
Milan, Policlinico
 
 —
A. Binda, L. Candelise, F. Nador, G. Pinardi, and L. Oliva (9); 
 
Parma
 
— A. Mombelloni, O. Ponari, and M. Squeri (11); 
 
Pavia
 
 — F. Barz-
izza, A. Cavallini, G. Micieli, G. Nappi, and I. Richichi (7); 
 
Perugia,
San Sisto
 
 — P. Caselli and E. Moretti (3); 
 
Perugia
 
 — G. Aisa,
E. Boschetti, N. Caputo, M.G. Celani, A. Del Favero, G. Nenci, S. Ric-
ci, E. Righetti, and U. Senin (18); 
 
Poggibonsi
 
 — M. Biotti, M. D’Et-
tore, and G. Fabrizi (9); 
 
Spoleto
 
 — S. Grasselli and F. Pezzella (6);
 
Trieste
 
 — L. Antonutti, F. Chiodo Grandi, D. Guerrini, A. Marzalli,
B. Pinamonti, R. Salvi, and C. Sammartini (33); and 
 
Vicenza
 
 —
P. Dudine, F. Ferro Milone, and M. Vicenzi (4). 
 
The Netherlands:
 
Almelo
 
 — J.W.M. ter Berg, H. J. Gelmers, J.A. Haas, and S.F. Linde-
boom (8); 
 
Amsterdam, Academic Medical Center
 
 — D. Herderschêe,
A. Hijdra, and M. Vermeulen (3); 
 
Amsterdam,
 
 
 
Free University
 
 — F.W.
Bertelsmann, G. J. Hazenberg, and J.C. Koetsier (10); 
 
Bergen op Zoom
 
— P. J.I.M. Berntsen, T.B. Gebbink, and F.M. Sleegers (6); 
 
Deventer
 
— J.A. van Beeck, W. J. Feikema, J.H.M. van Gasteren, A.N. Veltema,
and C. J.M. Vredeveld (1); 
 
Dordrecht
 
 — P.A.T. Carbaat, L.I.
Hertzberger, and R.P. Kleyweg (12); 
 
Goes
 
 — A.M. Boon, W.H.G.
Lieuwens, and F. Visscher (13); 
 
The Hague — W.F.M. Arts, A. Boon,
L.C.M. Moll, W.V.M. Perquin, J.T. J. Tans, R. Tonk, and A.W. de
Weerd (10); Groningen — H. Haaxma-Reiche, H. J.G.H. Oosterhuis,
and J.W. Snoek (3); Heerlen — C.L. Franke, J.F. Mirandolle, and P. J. J.
Koehler (27); Leiden — P.E. Briët and J. van Rossum (5); Maastricht
— J. Boiten, A.E. Boon, J. Lodder, and J. Nihom (15); Nieuwegein —
H.W. Mauser (2); Nijmegen — C.W.G.M. Frenken, E.F. J. Poels, M. J. J.
Prick, and W.I.M. Verhagen (12); Rotterdam, Dijkzigt — W. J. J.F. Hop-
penbrouwers, P. J. Koudstaal, and A. Staal (27); Rotterdam, Fransiscus
— P.R. Beneder, C. Bulens, and L.H. Penning de Vries-Bos (5); Til-
burg — A.A.W. Op de Coul, A.C.M. Leyten, C.C. Tijssen, and
R.L.L.A. Schellens (9); Utrecht — J.P.M. Cillessen, J. van Gijn, and
L. J. Kappelle (14); and Vlaardingen — J. J.M. Driesen, W.F. van Oude-
naarden, and J.C.B. Verhey (6). Norway: Alesund — O. J. Frisvold,
T. Hole, and O.R. Skogen (10); Arendal — B. Aslaksen, F. Gallefoss,
and K.O. Laake (5); Bodo — L.K. Berg (1); Drammen — S. Bals-
liemke and S. Ritland (8); Levanger — K. Hveem (2); Namsos —
O. Dehli (1); Oslo — U. Abildgaard and T. Dahl (13); and Skien —
B. Welund (1). Portugal: Coimbra, Centro Hospitalar — J.A. Grilo
Gonçalves and J.F. Palmeiro (29); Coimbra, University — R. Amaral,
C. Machado, A. Mestre, F. Ribeiro, and L. Sousa (3); Lisbon, Santa
Cruz — A. Vasco Salgado (4); Lisbon, San José — A. Baptista, J.M.
Candido, A.V. Morgado, and I.M.V. Ramires (41); Lisbon, Santa Ma-
ria — M. Crespo, J.M. Ferro, A.S. Franco, T.M.P. Melo, and V. Ol-
iveira (39); and Porto — A.F. Bastos Lima, M.M. Correia, J.C. Lopez,
R. Morgado, and M. Santos (21). Spain: Alcoy–Alicante — G. Grau,
J. Lopez, R. Martin, and J. Matias-Guiu (11); Barcelona, Bellvitge —
J. Alio, M. Calopa, F. Miralles, and F. Rubio (4); Barcelona, del Mar
— J. Fueyo, C. Gomez, L. Molina, L. D’Olhaberriague, and L. Soler-
Singla (11); Gerona — A. Dávalos, D. Genís, and J. Bassaganyas (9);
Madrid — P. Barreiro, E. Diez-Tejedor, and A. Frank (8); Tarragona
— J. Costa and R. Marés (3); and Valencia — L. Lainez and J. Sancho
(10). Sweden: Örebro — K.H. Hennerdal, N. Rudback, M. Samuels-
son, and P. Sigfridson (9); and Sundsvall — M. Hedenus (11). Swit-
zerland: Lausanne — J. Bogousslavsky, J. Ghika, L. Mariani,
B. Nater, and F. Schmid (27). United Kingdom: Aberdeen, Royal —
R. Knight (1); Aberdeen, Woodend — S. J.C. Hamilton and J. Kane (5);
Amersham — R. Bell and C.K. Foote (4); Edinburgh, City — T. Cassidy
and C.S. Gray (9); Edinburgh, Western — P.A.G. Sandercock, R. Sellar,
*CI denotes confidence interval.
Table 3. Multivariate Analysis of the Ischemic and
Hemorrhagic Complications That Occurred First in
the Study Patients.
VARIABLE
ADJUSTED RATE RATIO 
(95% CI*) P VALUE
INR
2.0
2.0 to 2.9
3.0 to 3.9
4.0 to 4.9
5.0
1.0
0.2 (0.1–0.6)
0.4 (0.1–1.1)
1.6 (0.6–4.6)
3.6 (1.2–11)
0.003
0.075
0.378
0.022
Age — yr
75
75
1.0
3.1 (1.5–6.4)
0.002
Systolic blood pressure at
entry — mm Hg
160
160
1.0
1.6 (0.6–3.9)
0.325
History of ischemic heart
disease
No
Yes
1.0
1.4 (0.6–3.4)
0.431
Cardiothoracic ratio 50 %
No
Yes
1.0
2.9 (1.4–5.9)
0.003
The New England Journal of Medicine 
Downloaded from nejm.org at ERASMUS UNIVERSITY on January 6, 2015. For personal use only. No other uses without permission. 
 Copyright © 1995 Massachusetts Medical Society. All rights reserved. 
10 THE NEW ENGLAND JOURNAL OF MEDICINE July 6, 1995
and C.P. Warlow (16); Keighley — J.G. Howe (4); King’s Lynn — J.C.
McGourty (2); Leeds — J. Bamford and M. Johnson (28); Leicester —
C.M. Castleden, G.D. Harper, B.N. Panayiotou, and T. Robinson (7);
Liverpool, Royal — D. Barer (19); Liverpool, Walton — P. Humphrey
(2); London — K. Kafetz and G. McElligott (6); Newcastle — D. Bates
and N.E.F. Cartlidge (1); Sheffield — G.S. Venables (49); and Wim-
bledon — P. Monro (1).
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